California is currently home to 5930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
Recruiting
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions and a single subcutaneous (SC) injection of AK006. The study will be conducted in 4 parts: a single-ascending dose part (Part A) in healthy participants, a multiple-ascending dose part (Part B) in healthy participants with an expanded cohort (Part C) in participants with... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: Site 601-014 (Part C), Bakersfield, California
Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Recruiting
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in esca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: City of Hope /ID# 253727, Duarte, California
Conditions: Acute Myeloid Leukemia
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Stanford Cancer Center, Palo Alto, California
Conditions: Metastatic Castration-resistant Prostate Cancer
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Recruiting
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping the... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
06/18/2024
Locations: Kaiser Permanente-Oakland, Oakland, California
Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Hoag Memorial Hospital, Newport Beach, California
Conditions: Colitis, Ulcerative
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California
Conditions: Myelodysplastic Syndromes
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is bei... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/18/2024
Locations: UCSF Benioff Children's Hospital - Oakland /ID# 258327, Oakland, California
Conditions: Crohn's Disease
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: The Oncology Institute Clinical Research, Cerritos, California
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Community Cancer Institute, Clovis, California
Conditions: Myelodysplastic Syndromes
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2024
Locations: Research Site, La Jolla, California
Conditions: Non-Muscle- Invasive Bladder Cancer
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
Recruiting
This is a single-center, prospective pilot study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatment (RT) for breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Breast Cancer
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Recruiting
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2024
Locations: Science 37, Culver City, California
Conditions: Narcolepsy